![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, June 21, 2005 1:16:44 PM
I only listed one study per ingredient above, but there are literally dozens of sucessful clinical trials for each ingredient that bear witness to their clinical efficacy against diabetes and/or prediabetic syndrome. That means that it is an objective scientific fact that this combination of subtances works. Period.
Here's the rub. The largest demographic for this product will be the lower or middle class. Why? Because, sadly, this demographic is more likely to get sick, because they are less likely to be able to afford comprehensive medical care and prevention.
If a rich patient is diagnosed as prediabetic, they can afford major diet and exercise changes, dieticians, personal trainers, even something as simple as a membership at the local Bally's, which can delay or prevent onset. On the other hand, chronically obese, blue-collar workers raising children on a shoestring budget cannot afford such things, and often cannot afford the time or copayment for anything except emergency medical treatment. Consequently, they are less likely to be detected as prediabetic, less likely to be able to derail prediabetic syndrome, and most likely to have initial diagnoses as full-blown diabetic.
An entry price of about $30 a bottle, or roughly $60 for a months supply, places the cost of the product well within reach of its main demand demographic, and also makes it's price comparable to what an individual within that demographic might expect to pay for a typical prescription co-payment. An effective, affordable, prescription-free adjunct or alternative to medical treatment is a sure-fire winner for those who can't or won't go to the doctor as often as they should. Just look at the widespread success of Prilosec OTC, and the cost per 30 day supply. It's doing MUCH better in bulk on the shelves of Wal Mart at low prices than Leptoprin is doing at $153 a bottle on T.V., for example. From a business standpoint, a hundred thousand bottles sold at $30 per bottle is far better than ten thousand sold at $60, and from a medical and ethical standpoint, the lower price places the product into more hands that need it.
For example, I can think of one elderly lady I personally know who needs the product, and who wants to try the product. However, she can't afford it because she's on social security. Her diabetes is not being properly controlled by the best prescription medicine can give her, and she is suffering ongoing physical deterioration as a result. Deterioration that could be prevented or reversed by HPB84. But medicare or medicaid would never pay for such a thing, so she will never get it. Is there not an ethical responsibility to make this product, which the research clearly demonstrates WILL help her, available to her?
Just some thoughts.
Albert
-----------------------------------------------------------------
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM